Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jun 20;60(7):4387-90.
doi: 10.1128/AAC.03074-15. Print 2016 Jul.

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study

Benjamin Miller  1 , Myra W Popejoy  2 , Ellie Hershberger  3 , Judith N Steenbergen  3 , John Alverdy  4
Affiliations
Clinical Trial

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study

Benjamin Miller et al. Antimicrob Agents Chemother. .

Abstract

Ceftolozane-tazobactam is active against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa In a subgroup analysis of patients with complicated intra-abdominal infections (cIAIs) involving P. aeruginosa from a phase 3 program, ceftolozane-tazobactam demonstrated potent in vitro activity against P. aeruginosa Clinical cure in the microbiologically evaluable population was 100% (26/26) for ceftolozane-tazobactam plus metronidazole and 93.1% (27/29) for meropenem. These findings support the use of ceftolozane-tazobactam in the management of cIAI when P. aeruginosa is suspected or confirmed. (This study has been registered at ClinicalTrials.gov under registration no. NCT01445665 and NCT01445678.).

PubMed Disclaimer

Figures

FIG 1
FIG 1
MIC distribution and clinical outcomes with ceftolozane-tazobactam and meropenem. (A) Distribution of ceftolozane-tazobactam and meropenem MICs for 69 Pseudomonas aeruginosa isolates identified at the screening visit (microbiological intent-to-treat population). (B) Clinical cure rate at the test-of-cure visit for patients with and without baseline P. aeruginosa infection, by treatment group (microbiologically evaluable population, which includes patients with pathogens at baseline who were susceptible or resistant to study drug).
See this image and copyright information in PMC

References

    1. Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, Malangoni M, Velmahos G, Coimbra R, Koike K, Leppaniemi A, Biffl W, Balogh Z, Bendinelli C, Gupta S, Kluger Y, Agresta F, Di Saverio S, Tugnoli G, Jovine E, Ordonez CA, Whelan JF, Fraga GP, Gomes CA, Pereira GA, Yuan KC, Bala M, Peev MP, Ben-Ishay O, Cui Y, Marwah S, Zachariah S, Wani I, Rangarajan M, Sakakushev B, Kong V, Ahmed A, Abbas A, Gonsaga RA, Guercioni G, Vettoretto N, Poiasina E, Diaz-Nieto R, Massalou D, Skrovina M, Gerych I, Augustin G, Kenig J, Khokha V, Trana C, Kok KY, Mefire AC, Lee JG, Hong SK, Lohse HA, Ghnnam W, Verni A, Lohsiriwat V, Siribumrungwong B, El Zalabany T, Tavares A, Baiocchi G, Das K, Jarry J, Zida M, Sato N, Murata K, Shoko T, Irahara T, Hamedelneel AO, Naidoo N, Adesunkanmi AR, Kobe Y, Ishii W, Oka K, Izawa Y, Hamid H, Khan I, Attri A, Sharma R, Sanjuan J, Badiel M, Barnabe R. 2014. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW study. World J Emerg Surg 9:37. doi:10.1186/1749-7922-9-37. - DOI - PMC - PubMed
    1. Center for Disease Dynamics Economics & Policy. 2013. ResistanceMap database: The Surveillance Network. USA Center for Disease Dynamics, Economics & Policy, Washington, DC: http://www.cddep.org/map Accessed 17 March 2016.
    1. European Centre for Disease Prevention and Control. 2013. Antimicrobial resistance surveillance in Europe 2013. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resista... Accessed 17 March 2016.
    1. Merck & Co., Inc. 2015. Zerbaxa prescribing information. Merck & Co., Inc., Whitehouse Station, NJ.
    1. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 55:2390–2394. doi:10.1128/AAC.01737-10. - DOI - PMC - PubMed

Publication types

Associated data